RxDoctor Payments Data

Prince Adotama, MD

Dermatology · New York, NYNPI 1700273349

Payments from drug & device makers

$192,605in general payments, 2019–2025

Across 194 payments — averaging $992.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$69K
  • Sanofi$30K
  • Pfizer$23K
  • Regeneron Healthcare Solutions, Inc.$21K
  • E.r. Squibb & Sons, L.L.C.$19K
  • Regeneron$17K
  • plus $13K from 16 others

What the payments were for

  • Consulting fees$112,88389%
  • Speaking & faculty fees$780%
  • Travel & lodging$8,5717%
  • Food & beverage$5,8685%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,605 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$67,677
Medicare patients
247
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab25$87,181
OpzeluraRuxolitinib Phosphate20$38,055
Tacrolimus70$8,597
Clobetasol Propionate50$2,241
Ketoconazole157$2,104
Azelaic Acid25$1,606
Triamcinolone Acetonide102$1,234
Doxycycline Monohydrate31$1,225
Clindamycin Phosphate29$1,020
Tretinoin20$741
Ciclopirox19$732
Ammonium Lactate39$634
Spironolactone12$483
Finasteride35$296
Minoxidil23$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$5,781$38,05520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →